person · Reporting owner

Ekman Lars

Disclosed activity across 5 companies

Tapewire entity: 46830
SEC CIK: 0001376117

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMARIN CORP PLC\UKAMRN · Entity 5970	Director	June 27, 2022	June 30, 2022
PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375	Director	May 15, 2026	May 16, 2026
SOPHIRIS BIO INC.SPHS · Entity 152909	Director	June 27, 2019	June 28, 2019
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	Director	June 24, 2022	June 28, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMARIN CORP PLC\UK

Report date June 27, 2022 · Filed June 30, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-06-27	Direct	115,919	Reported balance After 2022-06-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-27 · Grant · Acquired 115,919 · Balance 115,919 F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	93,750	Reported balance After 2022-06-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-27 · Grant · Acquired 93,750 · Balance 93,750 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year. F5: Not applicable. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.

F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year.

F5: Not applicable.

PROTHENA CORP PUBLIC LTD CO

Report date May 15, 2026 · Filed May 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.76 · Expires 2036-05-15	Direct	27,000	Reported balance After 2026-05-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-15 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

SOPHIRIS BIO INC.

Report date June 27, 2019 · Filed June 28, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2029-06-26	Direct	20,000	Reported balance After 2019-06-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-27 · Grant · Acquired 20,000 · Balance 20,000 F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program. F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period.

Filing footnotes · ownership attribution and instrument terms

F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program.

F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period.

Ultragenyx Pharmaceutical Inc.

Report date June 24, 2022 · Filed June 28, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,745	Reported balance After 2022-06-24 transaction · row 1 1 source row Row 1 · 2022-06-24 · Grant · Acquired 3,300 · Balance 17,745 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.57 · Expires 2032-06-24	Direct	6,245	Reported balance After 2022-06-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-24 · Grant · Acquired 6,245 · Balance 6,245 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.

F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Spark Therapeutics, Inc.

Report date December 17, 2019 · Filed December 17, 2019

Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-12-17 transaction · row 1 1 source row Row 1 · 2019-12-17 · Other · Disposed 3,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29	Direct	Reported balance After 2019-12-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30	Direct	Reported balance After 2019-12-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31	Direct	Reported balance After 2019-12-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-08-11	Direct	Reported balance After 2019-12-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-12-17 · Disposition to issuer · Disposed 37,203 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 26, 2020 Filed Jun 30, 2020 17:11 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	4,250	$0.00 Strike: $76.58	$0.00	Disclosure SEC source: 0001209191-20-039405 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2030-06-26 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021. Read SEC document
June 26, 2020 Filed Jun 30, 2020 17:11 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	2,550	$0.00	$0.00	Disclosure SEC source: 0001209191-20-039405 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021 Read SEC document
May 20, 2020 Filed May 22, 2020 20:37 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $11.33	$0.00	Disclosure SEC source: 0001567619-20-011030 · doc1.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2030-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2021 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	37,203	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0000899243-19-029428 · doc4.xml · derivative · entry 5 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,203 shares Expires 2024-08-11 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $56.22	$0.00	Disclosure SEC source: 0000899243-19-029428 · doc4.xml · derivative · entry 4 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-05-31 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $50.93	$0.00	Disclosure SEC source: 0000899243-19-029428 · doc4.xml · derivative · entry 3 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2027-05-30 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $81.53	$0.00	Disclosure SEC source: 0000899243-19-029428 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2028-05-29 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	OtherCommon Stock	3,000	$114.50	$343,500.00	Disclosure SEC source: 0000899243-19-029428 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. Read SEC document
November 12, 2019 Filed Nov 14, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	38,600	$0.00 Strike: $14.40	$0.00	Disclosure SEC source: 0001209191-19-056488 · doc4.xml · derivative · entry 3 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 38,600 shares Expires 2022-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 12, 2019 Filed Nov 14, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	38,600	$19.35	$746,759.46	Disclosure SEC source: 0001209191-19-056488 · doc4.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 12, 2019 Filed Nov 14, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	38,600	$14.40	$555,840.00	Disclosure SEC source: 0001209191-19-056488 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 05, 2019 Filed Nov 8, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	6,400	$0.00 Strike: $14.40	$0.00	Disclosure SEC source: 0001209191-19-055751 · doc4.xml · derivative · entry 3 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,600 Underlying: Ordinary Shares · 6,400 shares Expires 2022-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 05, 2019 Filed Nov 8, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	6,400	$18.00	$115,230.08	Disclosure SEC source: 0001209191-19-055751 · doc4.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 05, 2019 Filed Nov 8, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,400	$14.40	$92,160.00	Disclosure SEC source: 0001209191-19-055751 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	51,671	$0.00 Strike: $3.21	$0.00	Disclosure SEC source: 0001209191-19-048659 · doc4.xml · derivative · entry 7 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 51,671 shares Expires 2028-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	25,845	$0.00 Strike: $3.06	$0.00	Disclosure SEC source: 0001209191-19-048659 · doc4.xml · derivative · entry 6 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,845 shares Expires 2027-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	13,500	$0.00 Strike: $5.58	$0.00	Disclosure SEC source: 0001209191-19-048659 · doc4.xml · derivative · entry 5 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,500 shares Expires 2023-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	91,016	$15.01	$1,365,722.38	Disclosure SEC source: 0001209191-19-048659 · doc4.xml · nonDerivative · entry 4 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.70 to $15.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	51,671	$3.21	$165,863.91	Disclosure SEC source: 0001209191-19-048659 · doc4.xml · nonDerivative · entry 3 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	25,845	$3.06	$79,085.70	Disclosure SEC source: 0001209191-19-048659 · doc4.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 03, 2019 Filed Sep 6, 2019 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	13,500	$5.58	$75,330.00	Disclosure SEC source: 0001209191-19-048659 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 27, 2019 Filed Jun 28, 2019 20:19 UTC	SOPHIRIS BIO INC. SPHS · Entity 152909	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.78	$0.00	Disclosure SEC source: 0001209191-19-039474 · doc4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-26 F1 · security: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document
June 11, 2019 Filed Jun 13, 2019 20:40 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $58.74	$0.00	Disclosure SEC source: 0001209191-19-036806 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-11 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document
June 11, 2019 Filed Jun 13, 2019 20:40 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-036806 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document
May 30, 2019 Filed Jun 3, 2019 20:17 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	1,500	$0.00	$0.00	Disclosure SEC source: 0001609351-19-000056 · wf-form4_155959301909668.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. F3 · derivative.expiration_date: On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date. Vested shares are delivered to the reporting person on the vesting date. Read SEC document
May 30, 2019 Filed Jun 3, 2019 20:17 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	1,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-19-000056 · wf-form4_155959301909668.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document
May 22, 2019 Filed May 24, 2019 20:05 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $9.23	$0.00	Disclosure SEC source: 0001567619-19-012070 · doc1.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2029-05-22 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual general meeting in 2020 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document
May 20, 2019 Filed May 22, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	8,023	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-031858 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,023 Underlying: Ordinary Shares · 8,023 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On May 20, 2019, the Reporting Person was granted 8,023 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 20, 2019 Filed May 22, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	10,431	$0.00 Strike: $16.83	$0.00	Disclosure SEC source: 0001209191-19-031858 · doc4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,431 Underlying: Ordinary Shares · 10,431 shares Expires 2029-05-20 F1 · derivative.exercise_date: On May 20, 2019, the Reporting Person was granted an option to purchase 10,431 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in 2020. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	28,287	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · derivative · entry 14 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 28,287 shares Expires 2025-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	17,358	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · derivative · entry 13 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,358 shares Expires 2025-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	35,258	$0.00 Strike: $2.19	$0.00	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · derivative · entry 12 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 35,258 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	28,500	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · derivative · entry 11 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 28,500 shares Expires 2024-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	6,390	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · derivative · entry 10 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,390 shares Expires 2024-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	19,584	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · derivative · entry 9 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,584 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	36,700	$21.71	$796,830.40	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · nonDerivative · entry 8 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.48 to $22.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · ownership.direct: Please see the section titled "Remarks" below for additional information. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	98,677	$21.16	$2,088,074.39	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · nonDerivative · entry 7 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,700 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.48 to $21.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	28,287	$2.50	$70,717.50	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · nonDerivative · entry 6 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	17,358	$2.50	$43,395.00	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · nonDerivative · entry 5 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	35,258	$2.19	$77,215.02	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · nonDerivative · entry 4 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	28,500	$1.87	$53,295.00	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · nonDerivative · entry 3 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,390	$1.87	$11,949.30	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2019 Filed Mar 7, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	19,584	$1.03	$20,171.52	Disclosure SEC source: 0001209191-19-017567 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	100,416	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001209191-19-003496 · doc4.xml · derivative · entry 7 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,584 Underlying: Ordinary Shares · 100,416 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	7,496	$18.62	$139,602.51	Disclosure SEC source: 0001209191-19-003496 · doc4.xml · nonDerivative · entry 6 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.57 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	55,762	$18.16	$1,012,671.38	Disclosure SEC source: 0001209191-19-003496 · doc4.xml · nonDerivative · entry 5 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,496 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.57 to $18.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	48,711	$17.29	$842,140.12	Disclosure SEC source: 0001209191-19-003496 · doc4.xml · nonDerivative · entry 4 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,258 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $17.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	7,247	$15.96	$115,678.06	Disclosure SEC source: 0001209191-19-003496 · doc4.xml · nonDerivative · entry 3 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,969 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	21,200	$14.92	$316,397.28	Disclosure SEC source: 0001209191-19-003496 · doc4.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,216 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $15.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:16 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	100,416	$1.03	$103,428.48	Disclosure SEC source: 0001209191-19-003496 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.